【目的】为了探讨应用4D左心房自动定量分析(4D Auto LAQ)软件测定的左房容积和应变值对鉴别毛细血管前肺动脉高压和毛细血管后肺动脉高压的价值,并与肺-左心房应变偶联指数(ePLAGS)的鉴别能力进行比较。【方法】本研究为回顾性研究,共...【目的】为了探讨应用4D左心房自动定量分析(4D Auto LAQ)软件测定的左房容积和应变值对鉴别毛细血管前肺动脉高压和毛细血管后肺动脉高压的价值,并与肺-左心房应变偶联指数(ePLAGS)的鉴别能力进行比较。【方法】本研究为回顾性研究,共纳入了自2021年7月至2022年4月就诊于中山大学附属第一医院门诊或住院部的98例高概率肺动脉高压(PH)患者,收集所有患者的临床病史及实验室资料。根据肺动脉楔压(PAWP)将所有患者分为2组:毛细血管前PH组(PAWP≤15 mmHg)及毛细血管后PH组(PAWP>15 mmHg)。所纳入的患者均接受了经胸超声心动图检查,并应用4D Auto LAQ软件自动测量左房容积和应变参数。【结果】根据PAWP的数值,入选患者分为两组:毛细血管前PH组[n=39,年龄(53±24)岁]和毛细血管后PH组[n=59,年龄(57±18)岁]。与毛细血管前PH组相比,毛细血管后PH组的最大左心房容量指数(LAVImax)、最小左心房容量指数(LAVImin)和左心房射血前的容量指数(LAVIpreA)显著增加,而左心房储备期纵向应变值(LASr)和左心房导管期纵向应变值(LAScd)明显降低。多元逻辑回归分析显示,LAVImax[OR:1.40;95%CI:(1.052,1.872);P=0.021]和LAScd[OR:1.76;95%CI:(1.183,2.489);P=0.004]是检测毛细血管后PH的强大独立预测因子。ROC曲线分析表明,LAVImax(AUC=0.82,P<0.001)和LAScd(AUC=0.78,P<0.001)在预测毛细血管后PH组方面具有很高的辨别力,其临界值分别为35.69 mL/m^(2)(敏感性86%,特异性74%)和-9%(敏感性80%,特异性70%)。【结论】:应用4D auto LAQ测量的LAVImax和LAScd是区分毛细血管前和毛细血管后PH患者有价值的参数,且其鉴别能力优于肺-左心房应变偶联指数(ePLAGS)。展开更多
Objective To discuss the problems existing in the compensation of Chinese clinical trial participants and propose some suggestions for improving their rights.Methods The literature related to the participants’right t...Objective To discuss the problems existing in the compensation of Chinese clinical trial participants and propose some suggestions for improving their rights.Methods The literature related to the participants’right to compensation at home and abroad was searched to study the inadequacy of the compensation right for clinical trial participants in China from four aspects:insurance system,principle of attribution,legal relationship and compensation regulations.Then,some suggestions to improve the participants’right to compensation were proposed.Results and Conclusion China lacks clear legal norms for participants’right to compensation.There are problems such as unclear insurance rules and compensation rules,unclear contractual relationships between parties to clinical trials,and no laws and regulations to rely on for attribution and compensation.China should issue regulatory guidelines related to the right to compensation of participants in clinical trials,so that all parties in clinical trials can have rules to follow if there is the occurrence of injury,which can better protect the rights and interests of the participants.展开更多
文摘【目的】为了探讨应用4D左心房自动定量分析(4D Auto LAQ)软件测定的左房容积和应变值对鉴别毛细血管前肺动脉高压和毛细血管后肺动脉高压的价值,并与肺-左心房应变偶联指数(ePLAGS)的鉴别能力进行比较。【方法】本研究为回顾性研究,共纳入了自2021年7月至2022年4月就诊于中山大学附属第一医院门诊或住院部的98例高概率肺动脉高压(PH)患者,收集所有患者的临床病史及实验室资料。根据肺动脉楔压(PAWP)将所有患者分为2组:毛细血管前PH组(PAWP≤15 mmHg)及毛细血管后PH组(PAWP>15 mmHg)。所纳入的患者均接受了经胸超声心动图检查,并应用4D Auto LAQ软件自动测量左房容积和应变参数。【结果】根据PAWP的数值,入选患者分为两组:毛细血管前PH组[n=39,年龄(53±24)岁]和毛细血管后PH组[n=59,年龄(57±18)岁]。与毛细血管前PH组相比,毛细血管后PH组的最大左心房容量指数(LAVImax)、最小左心房容量指数(LAVImin)和左心房射血前的容量指数(LAVIpreA)显著增加,而左心房储备期纵向应变值(LASr)和左心房导管期纵向应变值(LAScd)明显降低。多元逻辑回归分析显示,LAVImax[OR:1.40;95%CI:(1.052,1.872);P=0.021]和LAScd[OR:1.76;95%CI:(1.183,2.489);P=0.004]是检测毛细血管后PH的强大独立预测因子。ROC曲线分析表明,LAVImax(AUC=0.82,P<0.001)和LAScd(AUC=0.78,P<0.001)在预测毛细血管后PH组方面具有很高的辨别力,其临界值分别为35.69 mL/m^(2)(敏感性86%,特异性74%)和-9%(敏感性80%,特异性70%)。【结论】:应用4D auto LAQ测量的LAVImax和LAScd是区分毛细血管前和毛细血管后PH患者有价值的参数,且其鉴别能力优于肺-左心房应变偶联指数(ePLAGS)。
基金Liaoning Pharmaceutical Industry Innovation and Development Strategy Research and Funding Project(2020lslktyb-095)National Medical Products Administration-Special Fund of Drug Regulatory Research Institute of Shenyang Pharmaceutical University(2021jgkx004)+1 种基金Shenzhen Maternity&Child Healthcare Hospital Science Foundation(2022(73))Shenzhen Health Economics Society Research Fund Project(202333).
文摘Objective To discuss the problems existing in the compensation of Chinese clinical trial participants and propose some suggestions for improving their rights.Methods The literature related to the participants’right to compensation at home and abroad was searched to study the inadequacy of the compensation right for clinical trial participants in China from four aspects:insurance system,principle of attribution,legal relationship and compensation regulations.Then,some suggestions to improve the participants’right to compensation were proposed.Results and Conclusion China lacks clear legal norms for participants’right to compensation.There are problems such as unclear insurance rules and compensation rules,unclear contractual relationships between parties to clinical trials,and no laws and regulations to rely on for attribution and compensation.China should issue regulatory guidelines related to the right to compensation of participants in clinical trials,so that all parties in clinical trials can have rules to follow if there is the occurrence of injury,which can better protect the rights and interests of the participants.
